<DOC>
	<DOCNO>NCT03088111</DOCNO>
	<brief_summary>This field study post-marketing requirement FDA evaluate clinical benefit ( course illness survival ) , safety pharmacokinetics obiltoxaximab administer patient part medical care treatment prophylaxis inhalational anthrax infection follow exposure Bacillus anthracis ( B. anthracis ) . The protocol implement individual receives obiltoxaximab suspect , probable , confirmed case inhalational anthrax due B. anthracis United States , include sporadic case , small incident and/or mass event . In case small anthrax incident , extent possible , information collect prospectively prespecified time point , except would interfere management subject 's illness . However , logistical complexity would likely accompany mass anthrax event , data study anticipate collect retrospectively . Both retrospective prospective data collection allow maximize information collection . This study collect data use obiltoxaximab anthrax infect exposed subject data collect inform understand clinical benefit safety obiltoxaximab .</brief_summary>
	<brief_title>An Open Label Field Study Anthim ( Obiltoxaximab ) Subjects Exposed B. Anthracis</brief_title>
	<detailed_description />
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Men woman ( include pregnant lactating woman ) child age receive obiltoxaximab part clinical care anthrax infection willing able give write informed consent legally acceptable representative ( minor , unconscious adult deceased subject ) participate study There exclusion criterion define study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AnthimÂ®</keyword>
	<keyword>Obiltoxaximab</keyword>
	<keyword>anthrax</keyword>
	<keyword>anti-toxin</keyword>
</DOC>